PRA Health Sciences Late Phase Services is participating in a global real world safety study program, mandated by various regulatory bodies, to confirm risk/benefit profile for a novel oral anticoagulant to assess the drug’s bleeding risk. Our ability to provide global operational oversight and efficiencies, ensure consistent communication with sites, and keep our patients engaged resulted in PRA becoming the client’s CRO of choice.
Beyond the First Step: What’s Next for COVID-19 Research
COVID-19 has sped up the process in terms of generating new kinds of vaccines and developing ways to gather real-world data. Read more about how this…
Join PRA in China 加入 PRA
PRA 重视、尊重和支持他人，践行 “以人为本”。欢迎与我们联系，了解加入PRA中国，一个目前已拥有 500 余名员工的团队。
Synthetic Control Arms: Considerations Around Definition, Drivers, and Design
Those that work in the biopharmaceutical or device industry are likely familiar with the term synthetic controls. But what exactly are synthetic…